YOUR SEARCH FOR Text 42 RESULTS
1 of Total
Portfolio: MPNs & GVHD, Hematology/Oncology, Dermatology & Inflammation & Autoimmunity | Incyte.com
… have a breadth of clinical programs within our portfolio across Myeloproliferative Neoplasms … (IAI), and Partnered Programs. NAVIGATE TO Portfolio Details Clinical Trials Our Portfolio …
2 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… underscoring confidence in commercial portfolio and R&D pipeline Conference Call … update on the Company’s clinical development portfolio. "In the second quarter of 2024, total …
3 of Total
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… a status update on the Company’s development portfolio. “Incyte has transformed as a Company … global launches have significantly expanded our portfolio; our robust development pipeline …
4 of Total
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guida
… update on the Company’s clinical development portfolio. “2021 was a year of important … year, we significantly expanded our commercial portfolio with several new approvals, including …
5 of Total
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… update on the Company’s clinical development portfolio. “Our total net product revenues grew … expected over the next several months.” Portfolio Updates MPNs and GVHD – key highlights …
6 of Total
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… update on the Company’s clinical development portfolio. "In the first quarter of 2024, total … featuring data from Incyte's dermatology portfolio were presented at the 2024 American …
7 of Total
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Ass
… it will present new data from its dermatology portfolio at the European Association of … the significant progress across our dermatology portfolio. The late-breaking data from the …
8 of Total
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… a status update on the Company’s development portfolio. “In the second quarter, we saw an … achieve clinical development success across our portfolio with positive outcomes from multiple …
9 of Total
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance
… update on the Company’s clinical development portfolio. "We are entering 2023 with … for strong growth with our current product portfolio and we expect to deliver many …
10 of Total
Drug Development & Scientific Innovation in Oncology and Inflammation & Autoimmunity | Incyte.com
… with maximum potential and building a strategic portfolio of compounds that are related or can … On . See How We Work to Innovate for Patients. PORTFOLIO At Incyte, we believe in the power of …